The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug Administration
Abstract
Background: In the US, manufacturers seeking approval to market a generic drug product must submit data demonstrating that the generic formulation provides the same rate and extent of absorption as (ie, is bioequivalent to) the innovator drug product. Thus, most orally administered generic drug products in the US are approved based on results of one or more clinical bioequivalence studies. Objective: To evaluate how well the bioequivalence measures of generic drugs approved in the US over a 12-year period compare with those of their corresponding innovator counterparts. Methods: This retrospective analysis compared the generic and innovator bioequivalence measures from 2070 single-dose clinical bioequivalence studies of orally administered generic drug products approved by the Food and Drug Administration (FDA) from 1996 to 2007 (12 y). Bioequivalence measures evaluated were drug peak plasma concentration (Cmax) and area under the plasma drug concentration versus time curve (AUC), representing drug rate and extent of absorption, respectively. The generic/innovator Cmax and AUC geometric mean ratios (GMRs) were determined from each of the bioequivalence studies, which used from 12 to 170 subjects. The GMRs from the 2070 studies were averaged. In addition, the distribution of differences between generic means and innovator means was determined for both Cmax and AUC. Results: The mean ± SD of the GMRs from the 2070 studies was 1.00 ± 0.06 for Cmax and 1.00 ± 0.04 for AUC. The average difference in Cmax and AUC between generic and innovator products was 4.35% and 3.56%, respectively. In addition, in nearly 98% of the bioequivalence studies conducted during this period, the generic product AUC differed from that of the innovator product by less than 10%. Conclusions: The criteria used to evaluate generic drug bioequivalence studies support the FDA's objective of approving generic drug formulations that are therapeutically equivalent to their innovator counterparts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schuirmann, D. J. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01068419 · Cited by 2,696
Clinical pharmacokinetics; concepts and applications
(1989) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(89)90348-0 · Cited by 2,223
Remington: The science and practice of pharmacy
(1996) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(96)90065-6 · Cited by 1,433
The utility of cyclodextrins for enhancing oral bioavailability
Carrier, R. L., Miller, L. A., & Ahmed, I. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.07.018 · Cited by 557
Remington : the science and practice of pharmacy
Troy, D. B. (2005) · Lippincott Williams & Wilkins eBooks · Cited by 532
Kesselheim, A. S. (2008) · JAMA · doi:10.1001/jama.2008.758 · Cited by 431
Clinical Pharmacokinetics: Concepts and Applications
(1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-6-500_4 · Cited by 247
Bioavailability and Bioequivalence: An FDA Regulatory Overview
Chen, M.-L., Shah, V., Patnaik, R., Adams, W., Hussain, A., Conner, D., Mehta, M., Malinowski, H., Lazor, J., Huang, S.-M., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1013319408893 · Cited by 221
Self-citationBioequivalence Testing -- A Need to Rethink
Kirkwood, T. B. L., & Westlake, W. J. (1981) · Biometrics · doi:10.2307/2530573 · Cited by 221
Bioequivalence and other unresolved issues in generic drug substitution
Meredith, P. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80340-5 · Cited by 213
Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.
Endrényi, L., Fritsch, S. R. S., & Yan, W. (1991) · PubMed · Cited by 137
Alloway, R. R., Isaacs, R. B., Lake, K. D., Hoyer, P. F., First, R. M., Helderman, H., Bunnapradist, S., Leichtman, A. B., Bennett, M. W., Tejani, A. H., et al. (2003) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00212.x · Cited by 104
A Modern View of Excipient Effects on Bioequivalence: Case Study of Sorbitol
Chen, M.-L., Straughn, A. B., Sadrieh, N. K., Meyer, M., Faustino, P. J., Ciavarella, A. B., Meibohm, B., Yates, C. R., & Hussain, A. S. M. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9120-4 · Cited by 91
Generic substitution: issues for problematic drugs.
Henderson, J. D., & Esham, R. H. (2001) · PubMed · Cited by 47
El‐Tahtawy, A., Jackson, A. J., & Ludden, T. M. (1994) · Pharmaceutical Research · doi:10.1023/a:1018906931100 · Cited by 38
El‐Tahtawy, A., Tozer, T. N., Harrison, F., Lesko, L. J., & Williams, R. (1998) · Pharmaceutical Research · doi:10.1023/a:1011961006297 · Cited by 33
Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate
Blakesley, V. A. (2005) · The AAPS Journal · doi:10.1208/aapsj070105 · Cited by 32
HENDERSON, J. D., & ESHAM, R. H. (2001) · Southern Medical Journal · doi:10.1097/00007611-200194010-00003 · Cited by 31
El‐Tahtawy, A., Jackson, A. J., & Ludden, T. M. (1995) · Pharmaceutical Research · doi:10.1023/a:1016288916410 · Cited by 30
Duquesnoy, C., Lacey, L. F., Keene, O. N., & Bye, A. (1998) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(97)10023-9 · Cited by 19
Why Rate of Absorption Inferences in Single Dose Bioequivalence Studies are Often Inappropriate
Basson, R. P., Ghosh, A., Cerimele, B. J., DESANTE, K. A., & Howey, D. C. (1998) · Pharmaceutical Research · doi:10.1023/a:1011974803996 · Cited by 16
Shaw, S. J., & Krauss, G. L. (2008) · Current Treatment Options in Neurology · doi:10.1007/s11940-008-0029-6 · Cited by 16
Patnaik, R. N. (2004) · Drugs and the pharmaceutical sciences · doi:10.1201/9780203026427.ch25 · Cited by 3
Bioequivalence Assessment: Approaches, Designs, and Statistical Considerations
Patnaik, R. N. (2004) · Cited by 2
Cited by
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
WOUTERS, O. J., KANAVOS, P. G., & McKEE, M. (2017) · The Milbank Quarterly · doi:10.1111/1468-0009.12279 · Cited by 287
Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide
Tamargo, J., Le Heuzey, J.-Y., & Mabo, P. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1832-0 · Cited by 276
Greenberg, E. R., Anderson, G. L., Morgan, D. R., Torres, J., Chey, W. D., Bravo, L. E., Dominguez, R. L., Ferreccio, C., Herrero, R., Lazcano-Ponce, E. C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60825-8 · Cited by 257
Trofe-Clark, J., Brennan, D. C., West-Thielke, P., Milone, M. C., Lim, M. A., Neubauer, R., Nigro, V., & Bloom, R. D. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.07.018 · Cited by 93
Qian, J., & Tanni, K. A. (2021) · Endocrine · doi:10.1007/s12020-021-02833-8 · Cited by 2
Metadata
- Authors
- Davit, B. M., Nwakama, P. E., Buehler, G. J., Conner, D. P., Haidar, S. H., Patel, D. T., Yang, Y., Yu, L. X., & Woodcock, J.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2009-09-23
- Volume
- 43
- Issue
- 10
- Pages
- 1583-1597
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2141163213
- Cited by
- 330
- References
- 24
- FWCI
- 35.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.